Switch to:
Also traded in: Belgium, Germany, Netherlands, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 15448.27
GLPG's Cash-to-Debt is ranked higher than
100% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. GLPG: 15448.27 )
Ranked among companies with meaningful Cash-to-Debt only.
GLPG' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.96  Med: 37.16 Max: 15448.27
Current: 15448.27
2.96
15448.27
Equity-to-Asset 0.70
GLPG's Equity-to-Asset is ranked higher than
52% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GLPG: 0.70 )
Ranked among companies with meaningful Equity-to-Asset only.
GLPG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.71 Max: 0.83
Current: 0.7
0.5
0.83
Interest Coverage N/A
GLPG's Interest Coverage is ranked lower than
99.99% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GLPG: N/A )
Ranked among companies with meaningful Interest Coverage only.
GLPG' s Interest Coverage Range Over the Past 10 Years
Min: 0.66  Med: 1.5 Max: N/A
Current: N/A
Piotroski F-Score: 7
Altman Z-Score: 8.35
Beneish M-Score: -1.18
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -8.87
GLPG's Operating Margin % is ranked lower than
55% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. GLPG: -8.87 )
Ranked among companies with meaningful Operating Margin % only.
GLPG' s Operating Margin % Range Over the Past 10 Years
Min: -226.08  Med: -18.64 Max: 1.78
Current: -8.87
-226.08
1.78
Net Margin % 41.70
GLPG's Net Margin % is ranked higher than
58% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. GLPG: 41.70 )
Ranked among companies with meaningful Net Margin % only.
GLPG' s Net Margin % Range Over the Past 10 Years
Min: -299.29  Med: -7.37 Max: 47.88
Current: 41.7
-299.29
47.88
ROE % 8.74
GLPG's ROE % is ranked higher than
72% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. GLPG: 8.74 )
Ranked among companies with meaningful ROE % only.
GLPG' s ROE % Range Over the Past 10 Years
Min: -41.46  Med: -5.25 Max: 17.79
Current: 8.74
-41.46
17.79
ROA % 6.25
GLPG's ROA % is ranked higher than
74% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. GLPG: 6.25 )
Ranked among companies with meaningful ROA % only.
GLPG' s ROA % Range Over the Past 10 Years
Min: -33.22  Med: -2.99 Max: 11.91
Current: 6.25
-33.22
11.91
ROC (Joel Greenblatt) % 371.58
GLPG's ROC (Joel Greenblatt) % is ranked lower than
54% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. GLPG: 371.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GLPG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1001.81  Med: -60.5 Max: 377.78
Current: 371.58
-1001.81
377.78
3-Year Revenue Growth Rate 0.90
GLPG's 3-Year Revenue Growth Rate is ranked lower than
56% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. GLPG: 0.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GLPG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -40  Med: 3.9 Max: 40
Current: 0.9
-40
40
GuruFocus has detected 4 Warning Signs with Galapagos NV $GLPG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GLPG's 30-Y Financials

Financials (Next Earnings Date: 2017-07-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

GLPG Guru Trades in Q2 2016

Jim Simons 8,100 sh (New)
» More
Q3 2016

GLPG Guru Trades in Q3 2016

Jim Simons 140,200 sh (+1630.86%)
» More
Q4 2016

GLPG Guru Trades in Q4 2016

Eaton Vance Worldwide Health Sciences Fund 99,828 sh (New)
Jim Simons 205,500 sh (+46.58%)
» More
Q1 2017

GLPG Guru Trades in Q1 2017

Jim Simons 311,200 sh (+51.44%)
Eaton Vance Worldwide Health Sciences Fund 99,828 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with GLPG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:NAS:TECH, NAS:NBIX, NAS:KITE, NAS:ACAD, NAS:BLUE, NAS:IONS, NAS:UTHR, OTCPK:BTGGF, NAS:CBPO, NAS:NKTR, NAS:EXEL, NYSE:XON, NAS:ICPT, NAS:BIVV, OTCPK:ABCZY, NAS:JUNO, NAS:ALNY, NAS:SAGE, NAS:RARE, NAS:LGND » details
Traded in other countries:GLPG.Belgium, GXE.Germany, GLPG.Netherlands, 0JXZ.UK, GLPGF.USA,
Headquarter Location:Belgium
Galapagos NV is a clinical-stage biotechnology company engaged in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need.

Galapagos is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Ratios

vs
industry
vs
history
PE Ratio 1533.78
GLPG's PE Ratio is ranked lower than
99.99% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. GLPG: 1533.78 )
Ranked among companies with meaningful PE Ratio only.
GLPG' s PE Ratio Range Over the Past 10 Years
Min: 12.55  Med: 42.82 Max: 1545.48
Current: 1533.78
12.55
1545.48
PE Ratio without NRI 1533.78
GLPG's PE Ratio without NRI is ranked lower than
99.99% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. GLPG: 1533.78 )
Ranked among companies with meaningful PE Ratio without NRI only.
GLPG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 48.32  Med: 57.61 Max: 1545.48
Current: 1533.78
48.32
1545.48
Price-to-Owner-Earnings 12.60
GLPG's Price-to-Owner-Earnings is ranked higher than
78% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. GLPG: 12.60 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GLPG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.06  Med: 10.8 Max: 13.99
Current: 12.6
9.06
13.99
PB Ratio 4.68
GLPG's PB Ratio is ranked lower than
64% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. GLPG: 4.68 )
Ranked among companies with meaningful PB Ratio only.
GLPG' s PB Ratio Range Over the Past 10 Years
Min: 2.03  Med: 5.04 Max: 8.06
Current: 4.68
2.03
8.06
PS Ratio 28.02
GLPG's PS Ratio is ranked lower than
87% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. GLPG: 28.02 )
Ranked among companies with meaningful PS Ratio only.
GLPG' s PS Ratio Range Over the Past 10 Years
Min: 5.99  Med: 23.99 Max: 57.56
Current: 28.02
5.99
57.56
Price-to-Free-Cash-Flow 15.45
GLPG's Price-to-Free-Cash-Flow is ranked higher than
70% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. GLPG: 15.45 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GLPG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.11  Med: 13.24 Max: 17.16
Current: 15.45
11.11
17.16
Price-to-Operating-Cash-Flow 15.14
GLPG's Price-to-Operating-Cash-Flow is ranked higher than
63% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. GLPG: 15.14 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GLPG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.88  Med: 12.98 Max: 16.81
Current: 15.14
10.88
16.81
EV-to-EBIT 48.04
GLPG's EV-to-EBIT is ranked higher than
79% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. GLPG: 48.04 )
Ranked among companies with meaningful EV-to-EBIT only.
GLPG' s EV-to-EBIT Range Over the Past 10 Years
Min: -41.7  Med: -11.7 Max: 56.2
Current: 48.04
-41.7
56.2
EV-to-EBITDA 44.89
GLPG's EV-to-EBITDA is ranked higher than
79% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. GLPG: 44.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
GLPG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -48.1  Med: -12.3 Max: 52.2
Current: 44.89
-48.1
52.2
Current Ratio 9.70
GLPG's Current Ratio is ranked higher than
78% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. GLPG: 9.70 )
Ranked among companies with meaningful Current Ratio only.
GLPG' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.7 Max: 9.7
Current: 9.7
1.22
9.7
Quick Ratio 9.70
GLPG's Quick Ratio is ranked higher than
78% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. GLPG: 9.70 )
Ranked among companies with meaningful Quick Ratio only.
GLPG' s Quick Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.61 Max: 9.7
Current: 9.7
1.22
9.7
Days Sales Outstanding 18.68
GLPG's Days Sales Outstanding is ranked higher than
62% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. GLPG: 18.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLPG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.05  Med: 18.68 Max: 114.23
Current: 18.68
7.05
114.23

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.80
GLPG's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. GLPG: -15.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GLPG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -51.6  Med: -8.25 Max: -2.2
Current: -15.8
-51.6
-2.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.49
GLPG's Price-to-Net-Cash is ranked higher than
54% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. GLPG: 5.49 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GLPG' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.81  Med: 4.35 Max: 8.31
Current: 5.49
3.81
8.31
Price-to-Net-Current-Asset-Value 5.21
GLPG's Price-to-Net-Current-Asset-Value is ranked higher than
54% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. GLPG: 5.21 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GLPG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.14  Med: 4.13 Max: 7.59
Current: 5.21
3.14
7.59
Price-to-Tangible-Book 4.70
GLPG's Price-to-Tangible-Book is ranked lower than
56% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. GLPG: 4.70 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GLPG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.3  Med: 3.72 Max: 6.2
Current: 4.7
2.3
6.2
Price-to-Intrinsic-Value-Projected-FCF 5.09
GLPG's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. GLPG: 5.09 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GLPG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 3.66  Med: 5.78 Max: 7.9
Current: 5.09
3.66
7.9
Price-to-Median-PS-Value 1.17
GLPG's Price-to-Median-PS-Value is ranked lower than
85% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. GLPG: 1.17 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GLPG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.5  Med: 0.81 Max: 1.77
Current: 1.17
0.5
1.77
Price-to-Graham-Number 3.75
GLPG's Price-to-Graham-Number is ranked lower than
99.99% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. GLPG: 3.75 )
Ranked among companies with meaningful Price-to-Graham-Number only.
GLPG' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.97  Med: 2.97 Max: 3.78
Current: 3.75
2.97
3.78
Earnings Yield (Greenblatt) % 2.08
GLPG's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. GLPG: 2.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GLPG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.8  Med: 2.5 Max: 3.3
Current: 2.08
1.8
3.3

More Statistics

Revenue (TTM) (Mil) $165.0
EPS (TTM) $ 0.01
Beta1.26
Short Percentage of Float0.00%
52-Week Range $49.43 - 94.88
Shares Outstanding (Mil)50.57
» More Articles for GLPG

Headlines

Articles On GuruFocus.com
Seven abstracts on filgotinib accepted by EULAR 2017 May 15 2017 
Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017 May 07 2017 
Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis a Apr 29 2017 
Galapagos reports first quarter 2017 results Apr 27 2017 
Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythemato Apr 25 2017 
Galapagos announces capital increase Apr 21 2017 
Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of Apr 21 2017 
Galapagos raises $338 million gross proceeds in a U.S. public offering Apr 17 2017 
Galapagos announces launch of proposed public offering Apr 17 2017 
Galapagos increases share capital through warrant exercises Apr 06 2017 

More From Other Websites
Galapagos creates new warrant plan May 17 2017
Seven abstracts on filgotinib accepted by EULAR 2017 May 15 2017
3 Top Biotech Stocks For May May 11 2017
Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017 May 07 2017
Galapagos NV :GLPG-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 May 04 2017
Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis... Apr 29 2017
ETFs with exposure to Galapagos NV : April 28, 2017 Apr 28 2017
Galapagos reports first quarter 2017 results Apr 27 2017
Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus... Apr 25 2017
Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of... Apr 21 2017
Galapagos raises $338 million gross proceeds in a U.S. public offering Apr 17 2017
Galapagos announces launch of proposed public offering Apr 17 2017
Galapagos increases share capital through warrant exercises Apr 06 2017
Galapagos doses first psoriatic arthritis patient with filgotinib Apr 05 2017
Galapagos Initiates 3 Phase II Studies for Filgotinib Apr 04 2017
Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib Apr 04 2017
The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial Mar 24 2017
Publication of the annual report and invitation to the annual and extraordinary shareholders'... Mar 23 2017
Galapagos Begins Cystis Fibrosis Treatment Study Mar 22 2017
Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067 Mar 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat